Comparative Pharmacology
Head-to-head clinical analysis: DESCOVY versus EMTRICITABINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DESCOVY versus EMTRICITABINE.
DESCOVY vs EMTRICITABINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DESCOVY is a fixed-dose combination of emtricitabine and tenofovir alafenamide. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV-1 reverse transcriptase by competing with the natural substrate deoxycytidine-5'-triphosphate and incorporating into viral DNA, causing chain termination. Tenofovir alafenamide is a prodrug of tenofovir, which is also an NRTI; it is taken up by cells and converted to tenofovir diphosphate, which inhibits HIV-1 reverse transcriptase via chain termination after incorporation into viral DNA.
Nucleoside reverse transcriptase inhibitor; phosphorylated to emtricitabine triphosphate which competes with endogenous deoxycytidine triphosphate and incorporates into viral DNA causing chain termination.
One tablet (emtricitabine 200 mg / tenofovir alafenamide 25 mg) orally once daily with or without food.
200 mg orally once daily, typically in combination with other antiretroviral agents.
None Documented
None Documented
Clinical Note
moderateEmtricitabine + Ribavirin
"Emtricitabine may increase the hepatotoxic activities of Ribavirin."
Clinical Note
moderateLamivudine + Emtricitabine
"The risk or severity of adverse effects can be increased when Lamivudine is combined with Emtricitabine."
Clinical Note
moderateGanciclovir + Emtricitabine
"The risk or severity of adverse effects can be increased when Ganciclovir is combined with Emtricitabine."
Clinical Note
moderateValganciclovir + Emtricitabine
TAF: 0.51 hours (intracellular tenofovir diphosphate ~150 hours). FTC: 10 hours (intracellular triphosphate >39 hours). Clinical context: Long intracellular half-life supports once-daily dosing.
Terminal elimination half-life is approximately 10 hours (range 8–12 hours) in adults with normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Tenofovir alafenamide (TAF): 80% excreted renally as unchanged drug via glomerular filtration and active tubular secretion; 15% recovered in feces. Emtricitabine (FTC): 70% excreted renally as unchanged drug via glomerular filtration and active tubular secretion; 14% as metabolites; remainder in feces.
Renal: approximately 86% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Biliary/fecal: minimal (<14% as unchanged drug and metabolites in feces).
Category C
Category C
Antiretroviral
Antiretroviral, NRTI
"The risk or severity of adverse effects can be increased when Valganciclovir is combined with Emtricitabine."